ClinicalTrials.gg
CompletedNCT02219256Updated May 3, 2017Results posted

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

A Phase 1 interventional study of TAK-079 and Placebo to TAK-079 in Autoimmune Disease, sponsored by Takeda. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-03.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.

Enrollment
38th of 65
74 · median 94
Started
2014
with 2 others
Phase 1
15 of 73
1 open now
Registered
16th of 73
by date
Lead sponsor
3 of 73
Takeda

Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 38th largest by enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2014, is one of 15 in phase 1, and was the 16th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Autoimmune Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetic and safety and tolerability profile of TAK-079 following a single intravenous (IV) infusion or subcutaneous (SC) administration at escalating dose levels in healthy participants.

Read the detailed description

The drug being tested in this study is TAK-079. TAK-079 is being tested to find a safe and well-tolerated dose and to assess how TAK-079 is processed by the body. This study will look at pharmacokinetics, side effects, and laboratory results in people who take TAK-079 and is designed as a randomized single dose-rising study.

Therefore, each subsequent cohort will not start until the previous cohort has completed and the results are reviewed. Each participant will receive TAK-079 or placebo once only as an IV infusion or by SC administration. The starting dose for IV will be 0.0003 mg/kg and SC dose of 0.01 or 0.03 mg/kg was determined based on the no-observed-adverse-effect-level (NOAEL) results from the 13-week good laboratory practice (GLP) monkey toxicology study. If this dose is well-tolerated, the next group will receive a higher dose, etc, until a maximal tolerated dose is reached with the highest dose not to exceed 1.0 mg/kg.

This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is up to 17 weeks. Participants will make 11 visits to the clinic, including one 10-day period of confinement in the clinic. All participants will be contacted by telephone 14 days after the last visit to the clinic for a follow-up assessment.

03

Conditions studied

  • Autoimmune Disease

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy male or female with no child bearing potential who is 18 to 55 years of age inclusive.
  2. The subject weighs at least 70 kilogram (kg) for cohort 1 and subsequent cohorts 50 kg (110.2 lb) and less than 100 kg (220.5 lb) and has a (BMI) range of 18.5 to 30 kilogram per square meter (kg/m\^2), inclusive at Screening Visit 1.
  3. A male participant who is non-sterilized and sexually active with a female partner of agrees to use adequate from signing of throughout the duration of the study and for 6 months after last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within the last 3 months or 5*T1/2 of the investigational compound,whichever is longer, prior to the day of study medication (Day 1).
  2. Has received any , within the last 3 months prior to Screening or is expected to receive any vaccinations during the study or for 1 month after the Day 78 Study Exit visit.
  3. Has received any other biologic medical products at any time in the past.
  4. Has a positive drug or alcohol screening result, or a history of drug or alcohol abuse.
  5. Has a positive test result for hepatitis or antibody.
  6. Has any signs of an acute infection or history of frequent or chronic infection, or herpes zoster.
  7. Has active or latent tuberculosis (TB)
  8. Considered unfit for the study by the Principal Investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Cohort 1: TAK-079 0.0003 mg/kg

    TAK-079 0.0003 mg/kg, infusion, intravenously, once.

    Drug: TAK-079

  • Experimental
    Cohort 2-9: TAK-079 TBD

    TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)

    Drug: TAK-079

  • Placebo comparator
    Placebo to TAK-079

    Placebo to TAK-079, infusion, intravenously or subcutaneously, once.

    Drug: Placebo to TAK-079

Interventions

  • TAK-079 solution

  • DrugPlacebo to TAK-079

    Placebo to TAK-079 solution

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE was assessed according to severity; mild (transient and easily tolerated by the participant), moderate (causes the participant discomfort and interrupts the participant's usual activities) and severe (causes considerable interference with the participant's usual activities).

    Time frame: First dose up to Day 94

  2. Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose

    Time frame: First dose up to Day 78

  3. Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose

    Time frame: First dose up to Day 78

  4. Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose

    Time frame: First dose up to Day 78

Secondary outcomes

  1. Cmax: Maximum Observed Serum Concentration for TAK-079

    Time frame: Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose

  2. AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079

    Time frame: Day 1 pre-dose and at multiple time points (up to Day 78) post-dose

  3. AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079

    Time frame: Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose

  4. Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)

    Results for ADA analysis were reported.

    Time frame: Baseline up to Day 78

07

Results

Posted May 3, 2017

Participant flow

Participants took part in the study at 1 investigative site in the United Kingdom (UK) from 01 August 2014 to 29 April 2016.

Participant flow — Overall Study
MilestoneTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Started1244466686666
Completed1244466686666
Not completed000000000000

Outcome measures

PrimaryNumber of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE was assessed according to severity; mild (transient and easily tolerated by the participant), moderate (causes the participant discomfort and interrupts the participant's usual activities) and severe (causes considerable interference with the participant's usual activities).

Time frame:
First dose up to Day 94
Reported as:
Number · participants
Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
participantsTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
TEAE: Mild632154235444
TEAE: Moderate501212431211
TEAE: Severe000000000000
SAE000000000000
PrimaryNumber of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
Time frame:
First dose up to Day 78
Reported as:
Number · participants
Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
participantsTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose110000020002
SecondaryCmax: Maximum Observed Serum Concentration for TAK-079
Time frame:
Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Serum Concentration for TAK-079
nanogram per milliliter (ng/mL)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Cmax: Maximum Observed Serum Concentration for TAK-079—————21.4 ± 8.3100.4 ± 51.7————23.0 ± 15.5
SecondaryAUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079
Time frame:
Day 1 pre-dose and at multiple time points (up to Day 78) post-dose
Reported as:
Mean · nanogram*day per milliliter (ng*day/mL)
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079
nanogram*day per milliliter (ng*day/mL)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079———————————90.4 ± 83.2
SecondaryAUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079
Time frame:
Day 1 pre-dose and at multiple time-points (up to Day 78) post-dose
Reported as:
Mean · ng*day/mL
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079
ng*day/mLTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-079———————————212 ± 103
SecondaryPercentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)

Results for ADA analysis were reported.

Time frame:
Baseline up to Day 78
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)
percentage of participantsTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Percentage of Participants With Positive Antidrug Antibody (ADA) and Neutralizing Antibody (Nab)00000016.7033.316.7016.7 ± 102.58826
PrimaryNumber of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Time frame:
First dose up to Day 78
Reported as:
Number · participants
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
participantsTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose622214644431
PrimaryNumber of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose
Time frame:
First dose up to Day 78
Reported as:
Number · participants
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose
participantsTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose833135154510

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 94 days after the last dose of double-blind study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-079 Pooled Placebo IV—0/12 (0%)11/12 (91.7%)
TAK-079 0.0003 mg/kg IV—0/4 (0%)3/4 (75%)
TAK-079 0.001 mg/kg IV—0/4 (0%)3/4 (75%)
TAK-079 0.003 mg/kg IV—0/4 (0%)3/4 (75%)
TAK-079 0.01 mg/kg IV—0/6 (0%)6/6 (100%)
TAK-079 0.03 mg/kg IV—0/6 (0%)6/6 (100%)
TAK-079 0.06 mg/kg IV—0/6 (0%)6/6 (100%)
TAK-079 Pooled Placebo SC—0/8 (0%)6/8 (75%)
TAK-079 0.03 mg/kg SC—0/6 (0%)6/6 (100%)
TAK-079 0.1 mg/kg SC—0/6 (0%)6/6 (100%)
TAK-079 0.3 mg/kg SC—0/6 (0%)5/6 (83.3%)
TAK-079 0.6 mg/kg SC—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 85
Most frequent other events
EventTAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SC
HeadacheNervous system disorders4/120/40/41/42/63/65/62/82/61/61/63/6
Dizziness posturalNervous system disorders0/120/40/40/40/61/65/61/80/61/60/61/6
Injection site erythemaGeneral disorders0/120/40/40/40/60/60/61/85/60/61/61/6
PyrexiaGeneral disorders0/120/40/40/41/61/63/60/80/60/61/60/6
NasopharyngitisInfections and infestations2/120/41/40/40/60/62/61/82/63/61/63/6
Injection site painGeneral disorders0/120/40/40/40/60/60/60/83/63/60/60/6
ChillsGeneral disorders0/120/40/40/40/60/62/60/80/60/60/61/6
Feeling hotGeneral disorders0/120/40/40/40/61/60/60/80/61/61/62/6
SomnolenceNervous system disorders0/120/40/40/40/61/62/60/80/61/60/60/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/121/40/40/40/61/61/61/80/62/60/61/6

Baseline characteristics

The safety analysis set included all participants who were enrolled, received 1 dose of study drug (after study drug dosing started) including those who did not complete all scheduled study visits.

Age, Continuous
Age, Continuous(years)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Mean35.5 ± 10.6123.5 ± 3.4242.3 ± 12.1232.8 ± 10.7236.2 ± 9.5232.3 ± 5.9235.7 ± 11.6034.9 ± 13.6136.7 ± 10.3331.0 ± 8.1540.8 ± 7.8327.7 ± 8.1634.3 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Female0000000100001
Male124446667666673
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
White83234556436251
Black or African American1001000100014
Asian20100101230313
Multiracial1110201000006
Region of Enrollment
Region of Enrollment(participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
United Kingdom124446668666674
Smoking Classification
Smoking Classification(participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Currently smoking40101300111113
Never smoked62233247344444
Ex-smoker22112121211117
Caffeine Classification
Caffeine Classification(participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Had caffeine consumption93316633365250
Had no caffeine consumption31130035301424
Alcohol Classification
Alcohol Classification(participants)TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Drinks everyday51213142412430
Never drank73233526254244
Height
Height(centimeter (cm))TAK-079 Pooled Placebo IVTAK-079 0.0003 mg/kg IVTAK-079 0.001 mg/kg IVTAK-079 0.003 mg/kg IVTAK-079 0.01 mg/kg IVTAK-079 0.03 mg/kg IVTAK-079 0.06 mg/kg IVTAK-079 Pooled Placebo SCTAK-079 0.03 mg/kg SCTAK-079 0.1 mg/kg SCTAK-079 0.3 mg/kg SCTAK-079 0.6 mg/kg SCTotal
Mean174.7 ± 9.17181.3 ± 6.90175.0 ± 8.04179.5 ± 10.91173.8 ± 1.47175.5 ± 7.97173.8 ± 7.03177.8 ± 7.91176.8 ± 3.31181.2 ± 8.80177.8 ± 6.68172.3 ± 4.32176.3 ± 7.32

2 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Headington, Oxford, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Fedyk ER, Zhao L, Koch A, Smithson G, Estevam J, Chen G, Lahu G, Roepcke S, Lin J, Mclean L. Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325. doi: 10.1111/bcp.14241. Epub 2020 Feb 22. PubMed 32045493 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 18, 2014
Start
Aug 2014
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
May 3, 2017
Last update
May 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02219256
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 18, 2014
Start date
Aug 2014
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
May 3, 2017
Last update
May 3, 2017

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezagitamab

Start the discussion